Thelansis

Idiopathic Inflammatory Myopathies (IIMs) Market Outlook Thelansis’s “Idiopathic Inflammatory Myopathies (IIMs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Inflammatory Myopathies (IIMs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events wil...

 Idiopathic Inflammatory Myopathies (IIMs) Market Outlook Thelansis’s “Idiopathic Inflammatory Myopathies (IIMs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Inflammatory Myopathies (IIMs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Idiopathic Inflammatory Myopathies (IIMs) Overview Idiopathic inflammatory myopathies (IIMs) represent a cluster of autoimmune disorders marked by muscle inflammation (myositis) and involvement of other organs, leading to broad organ dysfunction, heightened morbidity, and premature mortality. These conditions arise due to prolonged immune activity triggered by exposure to environme...

  Idiopathic inflammatory myopathies (IIMs) represent a cluster of autoimmune disorders marked by muscle inflammation (myositis) and involvement of other organs, leading to broad organ dysfunction, heightened morbidity, and premature mortality. Presently, IIMs are categorized into distinct subtypes: Dermatomyositis (DM) includes classic dermatomyositis, juvenile dermatomyositis, and clinical amyopathic dermatomyositis. These may be linked with connective tissue disorders (CTDs) and malignancies. Polymyositis (PM), comprising classical PM and nonspecific or overlap myositis, is often associated with CTDs. Autoimmune necrotizing myopathy, connected with malignancies, statin use, and CTDs. Sporadic IBM is occasionally associated with CTDs. These conditions arise due to prolonged immune activity triggered by exposure to environmental risk factors in individuals with a genetic predisposition. Diagnosing IIM can be straightforward when patients display...